Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled date : 2021 - 06 - 08 save search
Global Zika Virus Market Pipeline Spotlight Report 2021: Key Takeaways, Treatments, Epidemiology, Drugs, Probability of Success, Clinical Trial Landscape
Published: 2021-06-08 (Crawled : 20:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.37%
H: 1.09%
C: 0.98%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.88%
H: 0.74%
C: 0.5%
treatment drug trial
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial
Published: 2021-06-08 (Crawled : 20:00) - biospace.com/
CTXR | $0.8 -1.99% -2.02% 6.3M
|
Health Technology
|
| O: 3.92%
H: 1.51%
C: -3.02%
phase 3 trial milestone
Q2 Solutions and Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Trials
Published: 2021-06-08 (Crawled : 20:00) - biospace.com/
IQV | $227.17 -0.03% -0.79% 610K
|
Health Services
|
| O: 0.36%
H: 0.71%
C: 0.33%
unique clinical trials trial collaboration
Global $69.5 Billion Clinical Trials Market to 2028: Increasing R&D Promoting Outsourcing & Adoption of New Technology in Clinical Research
Published: 2021-06-08 (Crawled : 18:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 1.49%
H: 0.05%
C: -0.16%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.36%
H: 0.25%
C: -0.46%
ICLR | $291.74 -0.1% -0.1% 500K
|
Health Technology
|
| O: 0.5%
H: 0.77%
C: -0.63%
new technology clinical trials research technology trial
JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101
Published: 2021-06-08 (Crawled : 16:00) - biospace.com/
JAN | $3.67 0.27% 0.27% 150K
|
Industrial Services
|
| O: 0.28%
H: 22.24%
C: 10.5%
disease phase 2 phase 2b trial
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer
Published: 2021-06-08 (Crawled : 13:15) - biospace.com/
CRDF | $4.355 -3.22% -3.33% 830K
|
Health Services
|
| O: 0.9%
H: 5.47%
C: 2.93%
phase 2 onvansertib cancer trial pancreatic pancreas
Rising Industrial Demand for Silver Has the Mexican Mining Industry Buzzing
Published: 2021-06-08 (Crawled : 13:00) - prnewswire.com
HL | $5.28 0.74% 6.3M
|
Non-Energy Minerals
|
| O: -0.44%
H: 1.71%
C: -0.77%
FSM | $4.51 -1.31% 0.22% 3.9M
|
Non-Energy Minerals
|
| O: -0.58%
H: 0.74%
C: -2.35%
AG | $6.77 -1.02% 0.15% 7.1M
|
Non-Energy Minerals
|
| O: -0.85%
H: 1.2%
C: -1.37%
trial
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
Published: 2021-06-08 (Crawled : 13:00) - biospace.com/
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.43%
H: 0.27%
C: -2.08%
KNSA | $16.88 -0.41% -0.41% 410K
|
Health Technology
|
| O: 0.15%
H: 4.0%
C: 3.13%
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506, a Proposed Biosimilar of Simponi® (Golimumab)
Published: 2021-06-08 (Crawled : 13:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.27%
H: 0.23%
C: -1.14%
trial biosimilar
Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study
Published: 2021-06-08 (Crawled : 13:00) - biospace.com/
ORMP | $2.19 -6.01% -6.39% 240K
|
Health Technology
|
| O: 0.37%
H: 2.71%
C: 1.47%
insulin phase 3 enroll
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-06-08 (Crawled : 12:15) - inovio.com
INO 3 d | $10.22 -7.68% -8.32% 400K
|
Health Technology
|
| O: 2.49%
H: 0.46%
C: -0.69%
covid partnership vaccine phase 3 trial ino-4800
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
Published: 2021-06-08 (Crawled : 12:15) - globenewswire.com
OTLK P | $8.285 -3.78% -3.92% 230K
|
Health Technology
|
| O: 2.29%
H: 0.12%
C: -1.12%
phase 3 trial
NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.06%
H: 0.12%
C: -1.71%
phase 2 trial authorized application nivolumab
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
Published: 2021-06-08 (Crawled : 12:00) - globenewswire.com
IFRX | $1.275 0.79% 0.78% 120K
|
Health Technology
|
| O: 3.35%
H: 0.15%
C: -6.65%
trial cell carcinoma
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
AVXL | $3.8 -6.63% -7.11% 1.7M
|
Health Technology
|
| O: 4.51%
H: 0.41%
C: -0.46%
disease alzheimer phase 2 life science phase 2b trial anavex®2-73 anavex enroll alzheimer’s alzheimer's disease alzheimer's
Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
Published: 2021-06-08 (Crawled : 11:00) - globenewswire.com
ACRS | $1.235 0.41% 0.4% 650K
|
Health Technology
|
| O: 5.0%
H: 2.13%
C: -20.17%
phase 2 positive dermatitis topline trial atopic dermatitis phase 2b
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
Published: 2021-06-08 (Crawled : 11:00) - biospace.com/
PDSB | $2.89 6.25% 5.88% 1.1M
|
Health Technology
|
| O: 18.72%
H: 3.94%
C: 0.0%
presentation phase 2 biotech iot
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.